Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial.

AIMS Chronic heart failure is associated with maladaptive and prolonged neurohormonal and pro-inflammatory cytokine activation causing a metabolic shift favouring catabolism, vasodilator incapacity, and loss of skeletal muscle bulk and function. In men, androgens are important determinants of anabolic function and physical strength and also possess anti-inflammatory and vasodilatory properties. METHODS AND RESULTS We conducted a randomized, double-blind, placebo-controlled parallel trial of testosterone replacement therapy (5 mg Androderm) at physiological doses in 76 men (mean+/-SD, age 64+/-9.9) with heart failure (ejection fraction 32.5+/-11%) over a maximum follow-up period of 12 months. The primary endpoint was functional capacity as assessed by the incremental shuttle walk test (ISWT). At baseline, 18 (24%) had serum testosterone below the normal range and bioavailable testosterone correlated with distance walked on the initial ISWT (r=0.3, P=0.01). Exercise capacity significantly improved with testosterone therapy compared with placebo over the full study period (mean change +25+/-15 m) corresponding to a 15+/-11% improvement from baseline (P=0.006 ANOVA). Symptoms improved by at least one functional class on testosterone in 13 (35%) vs. 3 (8%) on placebo (P=0.01). No significant changes were found in handgrip strength, skeletal muscle bulk by cross-sectional computed tomography, or in tumour necrosis factor levels. Testosterone therapy was safe with no excess of adverse events although the patch preparation was not well tolerated by the study patients. CONCLUSION Testosterone replacement therapy improves functional capacity and symptoms in men with moderately severe heart failure.

[1]  K. Channer,et al.  The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. , 2004, The Journal of clinical endocrinology and metabolism.

[2]  C. Peers,et al.  Testosterone is a potent inhibitor of L-type Ca(2+) channels. , 2004, Biochemical and biophysical research communications.

[3]  R. Jones,et al.  Testosterone treatment for men with chronic heart failure , 2004, Heart.

[4]  K. Swedberg,et al.  Decreasing one-year mortality and hospitalization rates for heart failure in Sweden; Data from the Swedish Hospital Discharge Registry 1988 to 2000. , 2003, European heart journal.

[5]  Thomas R. Riley,et al.  A Randomized Double-blind Placebo-controlled Trial , 2004 .

[6]  Harlan M Krumholz,et al.  Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure. , 2003, Journal of the American College of Cardiology.

[7]  D. Sane,et al.  The cardiovascular effects of erythropoietin. , 2003, Cardiovascular research.

[8]  J. Karjalainen,et al.  Anabolic androgenic steroids produce dose-dependant increase in left ventricular mass in power atheletes, and this effect is potentiated by concomitant use of growth hormone. , 2003, International journal of sports medicine.

[9]  K. Channer,et al.  Acute haemodynamic effects of testosterone in men with chronic heart failure. , 2003, European heart journal.

[10]  M. Anastasiou-Nana,et al.  Hormonal profile in patients with congestive heart failure. , 2003, International journal of cardiology.

[11]  S. Anker,et al.  How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. , 2002, International journal of cardiology.

[12]  Daniel Levy,et al.  Long-term trends in the incidence of and survival with heart failure. , 2002, The New England journal of medicine.

[13]  H. Elliott Epidemiology, Aetiology and Prognosis of Hypertension , 2002 .

[14]  J. Townend,et al.  Incremental shuttle walk test in the assessment of patients for heart transplantation , 2001, Heart.

[15]  L. Woodhouse,et al.  Proof of the effect of testosterone on skeletal muscle. , 2001, The Journal of endocrinology.

[16]  V. Edgerton,et al.  Anabolic steroids increase exercise tolerance. , 2001, American journal of physiology. Endocrinology and metabolism.

[17]  M. Romano [Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina. A randomized, double-blind, placebo-controlled study]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[18]  S. Nitter‐Hauge,et al.  Immunomodulating Therapy With Intravenous Immunoglobulin in Patients With Chronic Heart Failure , 2001, Circulation.

[19]  F. Morales,et al.  Shuttle versus six-minute walk test in the prediction of outcome in chronic heart failure. , 2000, International journal of cardiology.

[20]  A. Iranmanesh,et al.  Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. , 2000, The Journal of clinical endocrinology and metabolism.

[21]  K. Nakao,et al.  The plasma levels of dehydroepiandrosterone sulfate are decreased in patients with chronic heart failure in proportion to the severity. , 2000, The Journal of clinical endocrinology and metabolism.

[22]  Simon Stewart,et al.  Epidemiology, aetiology, and prognosis of heart failure , 2000, Heart.

[23]  A. Negro-Vilar Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new millennium. , 1999, The Journal of clinical endocrinology and metabolism.

[24]  F. Morales,et al.  A shuttle walk test for assessment of functional capacity in chronic heart failure. , 1999, American heart journal.

[25]  M. Paterni,et al.  Effects of anabolic-androgenic steroids on weight-lifters' myocardium: an ultrasonic videodensitometric study. , 1999, Medicine and science in sports and exercise.

[26]  M. Van Loan,et al.  Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss. , 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[27]  E. Barrett-Connor,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Bioavailable Testosterone and Depressed Mood in Older Men: The Rancho Bernardo Study , 2022 .

[28]  H. Tomoda,et al.  Effect of oxymetholone on left ventricular dimensions in heart failure secondary to idiopathic dilated cardiomyopathy or to mitral or aortic regurgitation. , 1999, The American journal of cardiology.

[29]  D. Brooks,et al.  The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. , 1998, Chest.

[30]  A. Klibanski,et al.  Effects of Androgen Administration in Men with the AIDS Wasting Syndrome , 1998, Annals of Internal Medicine.

[31]  S. Arver,et al.  Long‐term efficacy and safety of a permeation‐enhanced testosterone transdermal system in hypogonadal men , 1997, Clinical endocrinology.

[32]  S. Anker,et al.  Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. , 1997, Journal of the American College of Cardiology.

[33]  P. Ponikowski,et al.  Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. , 1997, Circulation.

[34]  W. Mcconathy,et al.  Left Ventricular Size and Function in Elite Bodybuilders Using Anabolic Steroids , 1997, Clinical journal of sport medicine : official journal of the Canadian Academy of Sport Medicine.

[35]  A. Iranmanesh,et al.  Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study. , 1996, The Journal of clinical endocrinology and metabolism.

[36]  R. Francis,et al.  Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. , 1996, Bone.

[37]  T. Noakes,et al.  Anabolic-androgenic steroid increases running endurance in rats. , 1995, Medicine and science in sports and exercise.

[38]  Davis Wm,et al.  Nandrolone decanoate reduces the premature mortality of cardiomyopathic hamsters. , 1993 .

[39]  F. Giada,et al.  Anabolic steroid use in body builders: an echocardiographic study of left ventricle morphology and function. , 1991, International journal of sports medicine.

[40]  P. Björntorp,et al.  Effects of testosterone on muscle insulin sensitivity and morphology in female rats. , 1990, The American journal of physiology.

[41]  R. Tremblay,et al.  Plasma concentrations of free and non-TeBG bound testosterone in women on oral contraceptives. , 1974, Contraception.